前列腺癌症市场:KOL的洞察

本报告提供全球前列腺癌症市场相关调查，提供市场概要，以及已上市治疗方法，开发平台趋势，未来预测等资讯。

目录

摘要整理

现在及未来的治疗流程

调查目的

下一代雄激素受体抑制剂

• 已上市药物
  • Xtandi (enzalutamide; Astellas Pharma/Pfizer)
  • Erleada (apalutamide; Johnson & Johnson)
  • Nubeqa (darolutamide; Bayer/Orion)

新製剂雄激素消除疗法

• 已上市药物
  • Orgovyx (relugolix; Sumitomo Pharma/Takeda)

PARP抑制剂

• 已上市药物
  • Rubraca (rucaparib; Pharmaand GmbH)
  • Lynparza (olaparib; AstraZeneca)
  • Talzenna (talazoparib; Pfizer)
• 开发平台药物
  • Saruparib (AstraZeneca)

PD-1/PD-L1查核点抑制剂

• 开发平台药物
  • Tecentriq (atezolizumab; Genentech/Roche)
  • Keytruda (pembrolizumab; Merck & Co.)

放射线治疗

• 已上市药物
  • Xofigo (radium-223 dichloride; Bayer)
  • Pluvicto (Lutetium-177 PSMA 617; Novartis)
• 开发平台药物
  • [Lu-177]-PNT2002 (Lantheus/POINT Biopharma)

AKT抑制剂

• 开发平台药物
  • Truqap (capivasertib; AstraZeneca)

週期蛋白依赖型激梅抑制剂

• 开发平台药物
  • Verzenio (abemaciclib; Eli Lilly and Company)

今后的治疗趋势

附录

Delve into the evolving landscape of prostate cancer treatment with insights from 12 key opinion leaders. This report explores the future of therapies like Xtandi, Erleada, and Orgovyx, the impact of PARP inhibitors, and the potential of novel treatments. Understand the challenges and opportunities in addressing unmet needs and the role of AI in advancing care.

Key questions answered:

• How is the use of Xtandi expected to evolve in the next three to five years?
• What is the clinical experience with Erleada, and how significant is its Phase III PROTEUS study?
• Can Orgovyx challenge conventional ADTs in clinical practice?
• How are PARP inhibitors impacting the treatment paradigm for prostate cancer
• What role might immune checkpoint inhibitors play in prostate cancer treatment?
• How significant is the approval of Pluvicto for metastatic prostate cancer, and what are its benefits over Xofigo?

Key brands covered in this report:

Companies:

Table of Contents

Executive summary

Current and future treatment algorithm

Research objectives

Next-generation androgen receptor inhibitors

• Marketed drugs
  • Xtandi (enzalutamide; Astellas Pharma/Pfizer)
  • Erleada (apalutamide; Johnson & Johnson)
  • Nubeqa (darolutamide; Bayer/Orion)

Novel formulation androgen-deprivation therapies

• Marketed drugs
  • Orgovyx (relugolix; Sumitomo Pharma/Takeda)

PARP inhibitors

• Marketed drugs
  • Rubraca (rucaparib; Pharmaand GmbH)
  • Lynparza (olaparib; AstraZeneca)
  • Talzenna (talazoparib; Pfizer)
• Pipeline drugs
  • Saruparib (AstraZeneca)

PD-1/PD-L1 checkpoint inhibitors

• Pipeline drugs
  • Tecentriq (atezolizumab; Genentech/Roche)
  • Keytruda (pembrolizumab; Merck & Co.)

Radiation-based therapies

• Marketed drugs
  • Xofigo (radium-223 dichloride; Bayer)
  • Pluvicto (Lutetium-177 PSMA 617; Novartis)
• Pipeline drugs
  • [Lu-177]-PNT2002 (Lantheus/POINT Biopharma)

AKT inhibitors

• Pipeline drugs
  • Truqap (capivasertib; AstraZeneca)

Cyclin-dependent kinase inhibitors

• Pipeline drugs
  • Verzenio (abemaciclib; Eli Lilly and Company)

Future treatment trends

• Key insights summary

Appendix

• KOL details
  • KOLs from North America
  • KOLs from Europe